Medidata tips wearables data to enter regulatory filings by 2020

Glen De Vries

Medidata ($MDSO) president Glen de Vries has predicted drug developers will begin presenting digital biomarkers as evidence to regulators and payers within five years, Outsourcing-Pharma reports. De Vries highlighted the six-minute walk test--which is used in Duchenne muscular dystrophy trials--as one endpoint that could be improved by using wearables to gather digital biomarkers. Article

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.